Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
To the Editor: Drs Bhatt and Topol discussed
the role of glycoprotein (Gp) IIb/IIIa inhibitors in acute coronary syndromes,1 but did not comment on the use of these agents
in patients who have received fibrinolytic therapy. It is not uncommon for
patients who have received such treatment to require further acute intervention.
Are there any data about the risk-benefit ratio of Gp IIb/IIIa agents in patients
who may subsequently require urgent angioplasty following failed fibrinolytic
Ring BL. Glycoprotein Inhibitors and Fibrinolysis in Myocardial Infarction. JAMA. 2000;284(24):3124-3125. doi:10.1001/jama.284.24.3123